Company Overview
iTonic Holdings Ltd., operating under the ticker PTHL, functions as a healthcare solutions provider focused on the development and commercialization of treatment software and devices specifically designed for brachytherapy procedures. The company operates within the Healthcare sector, with its specific industry classification falling under Medical Devices, a field where proprietary technology is critical for delivering precise radioactive particle implantation for cancer treatment. As of the latest reporting period, the entity maintains a market capitalization of $22.30M and employs a workforce of 10 individuals to support its operations. These financial figures indicate that iTonic Holdings Ltd. is a micro-cap entity with limited revenue generation relative to its valuation multiple, suggesting a small-scale operation that relies heavily on intellectual property rather than broad commercial volume. The disparity between its modest market cap and high valuation multiples highlights the speculative nature often associated with early-stage medical device developers that have yet to achieve profitability.
Financial Health
The company reported a trailing twelve-month revenue of $305,215, yet this top-line figure masks a significant operational challenge as the net income for the same period was a loss of $-2,412,952. This massive gap between revenue and net income reveals an extremely fragile cost structure where expenses, likely driven by R&D and regulatory compliance costs, vastly outpace the income generated from sales. The business also recorded an EBITDA of $-2,523,650 and generated negative free cash flow of $-2,674,562, indicating that the company is currently burning through cash reserves without generating sufficient operating liquidity. In terms of profitability metrics, the gross margin stands at 82.9%, which suggests that the cost of goods sold is low relative to sales, but the operating margin is a staggering -3081.9%, and the profit margin is listed at 0.0%, reflecting the deep losses incurred after accounting for all operating expenses. The balance sheet shows a cash position of $3.21M against total debt of $139,595, resulting in a debt-to-equity ratio of 2.95, which technically indicates a leveraged position despite the low absolute debt amount due to the small equity base. However, the current ratio is an exceptionally high 11.69, which indicates that the company holds a substantial surplus of current assets relative to its short-term liabilities, providing a buffer against immediate liquidity pressures. Furthermore, the return on equity is -101.6% and the return on assets is -49.0%, metrics that reveal management is currently unable to generate positive returns on the capital invested in the business.
Valuation Assessment
The P/E Ratio (TTM) and Forward P/E are both listed as N/A, which implies that the difference between them is irrelevant because the company has no positive earnings to value, signaling that traditional earnings-based valuation methods are not applicable at this stage. The price-to-book ratio is 3.25, indicating that the market values the company at more than three times its net book value, which suggests a significant market premium assigned to its proprietary technology and future potential despite current losses. Additionally, the price-to-sales ratio is 73.07, and the EV/EBITDA is -2.90, suggesting that the market is pricing the stock based on revenue multiples and cash flow potential rather than current profitability, a common characteristic of biotech and medical device firms in development phases. Regarding trading range, the 52-week high is $32.00 and the 52-week low is $0.39, meaning the stock has experienced extreme volatility within this range. The current price sits significantly closer to the low end of this spectrum, reflecting the uncertainty surrounding the company's ability to turn operations profitable. The beta value is listed as N/A, which means there is insufficient historical volatility data available to calculate price movement relative to the broader market index.
Growth & Income
The company experienced a revenue growth (YoY) of -67.9%, while earnings growth (YoY) is N/A due to the lack of prior period profitability. Since earnings are negative, they are not growing faster than revenue in a traditional sense, but rather the company is contracting its revenue base while simultaneously incurring losses, which implies a challenging operational trajectory. As the dividend yield is N/A and the payout ratio is 0.0%, the company does not distribute dividends to shareholders. Consequently, the firm reinvests its limited resources, if any remain after expenses, into growth initiatives rather than paying out income to investors. The overall growth and income profile is defined by negative revenue expansion and a complete absence of dividend income, positioning the asset purely as a speculative vehicle dependent on future operational success rather than current financial performance.